PHVS
Pharvaris N.V.Healthcare·Biotechnology
$30.16
$2.1B market cap
Revenue
$0.0M
Free Cash Flow
$-87.6M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-releas
2-Year Price History
$29.68+56.5%
Quarterly Financials & Projections
Quarterly Waterfall (EUR M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -44.9 | -45.0 | -39.9 | -49.6 | -49.6 | -0.1 | 247.2 | 0.7 | 65.3 | -340.7% | -511.2x | -- |
| Act | 2025-Q4 | 0.0 | -47.5 | -47.6 | -46.7 | -38.0 | -38.0 | -0.0 | 291.7 | 0.8 | 59.2 | -214.1% | -- | -- |
Valuation & Metrics
Market Stats
Price$30.16
Market Cap$2.1B
Enterprise Value$1.5B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-4.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-86.6M
Free Cash Flow$-87.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-277.4%
WC Change % Rev0.0%
Interest Coverage-1052.0x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.1M
Days to Cover3.5
Change (vs Prior)-6.8%
Need at least 2 settlement dates for chart
Employees
Headcount108
Revenue / Employee$0
Gross Profit / Employee$-986
Cash Runway
33.9months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
81.6%(+46.6% YoY)
101 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
1.6%(+1.2% YoY)
6 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.3% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. | $227M | $21.99 | +$0 | +$14.1M | -4.6% | $2.15B |
| FMR LLC | $178M | $26.20 | −$3.2M | +$25.1M | -0.0% | $1.89T |
| Foresite Capital Management IV, LLC | $135M | $20.83 | +$0 | +$10.4M | -5.1% | $237M |
| venBio Partners LLC | $131M | $19.11 | +$0 | +$9.9M | -5.2% | $281M |
| VIKING GLOBAL INVESTORS LP | $103M | $17.41 | +$0 | +$0 | +1.1% | $35.75B |
| EQT Fund Management S.a r.l. | $96.7M | $24.95 | +$0 | +$96.7M | -18.4% | $1.02B |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $88.3M | $22.94 | +$0 | +$31.3M | -0.8% | $7.18B |
| Bain Capital Life Sciences Investors, LLC | $75.6M | $15.14 | −$3.6M | −$17.7M | -0.1% | $1.11B |
| WELLINGTON MANAGEMENT GROUP LLP | $59.9M | $25.51 | +$6.0M | +$59.9M | -0.3% | $533.98B |
| Commodore Capital LP | $54.2M | $24.83 | +$834K | +$213K | -0.0% | $1.73B |
| Novo Holdings A/S | $49.4M | $15.82 | +$0 | +$706K | -3.3% | $1.23B |
| Saturn V Capital Management LP | $33.9M | $25.71 | +$1.7M | +$33.9M | +1.8% | $552M |
| Point72 Asset Management, L.P. | $28.4M | $25.98 | +$8.3M | +$27.0M | +0.9% | $54.88B |
| Cormorant Asset Management, LLC | $28.3M | $21.83 | −$2.3M | −$13.2M | -2.4% | $1.95B |
| Sofinnova Investments, Inc. | $23.1M | $26.44 | +$2.1M | +$6.4M | +2.7% | $1.94B |
| 5AM Venture Management, LLC | $22.5M | $23.67 | +$0 | +$0 | +1.3% | $360M |
| Polar Capital Holdings Plc | $22.1M | $27.17 | +$15.3M | +$22.1M | +1.5% | $22.76B |
| BlackRock, Inc.Passive | $21.4M | $24.51 | +$1.4M | +$15.9M | -0.2% | $5.69T |
| Soleus Capital Management, L.P. | $19.8M | $17.35 | +$0 | −$3.2M | -0.9% | $2.47B |
| Rock Springs Capital Management LP | $18.2M | $23.14 | +$625K | +$625K | -1.9% | $1.65B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-2.14%
avg per quarter
Holders (ex-self)
-2.51%
excl. this stock
Buyers (this Q)
+3.18%
44 buyers · $0.07B in
Sellers (this Q)
+0.13%
35 sellers · $0.05B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-0.2%
how holders react when this stock falls
On quiet Qs
+0.8%
−10% to +10% baseline
On rallies (+10%+)
+24.2%
how they react when this stock rises
Holders' portfolio flow this Q
-2.6%
outflows — trims may be forced
Sellers' portfolio flow this Q
+3.1%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.8%
Holder mid (any stock)
-2.9%
Holder rally (any stock)
-6.6%
Biggest decreases this quarter
Bain Capital Life Sciences Investors, LLC−$3.6Mα-0.1FMR LLC−$3.2Mα-0.0Cormorant Asset Management, LLC−$2.3Mα-2.4JANE STREET GROUP, LLCexited−$2.0MSPHERA FUNDS MANAGEMENT LTD.exited−$1.8MPatient Square Capital LP−$1.4Mα+3.2BALYASNY ASSET MANAGEMENT LLC−$961Kα-0.4MARSHALL WACE, LLPexited−$883KVerition Fund Management LLCexited−$497KDaiwa Securities Group Inc.exited−$6K
Top-5 holders · 46.5%
GENERAL ATLANTIC, L.P.--
FMR LLC--
Foresite Capital Management IV, LLC--
venBio Partners LLC--
VIKING GLOBAL INVESTORS LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
GENERAL ATLANTIC, L.P.8.0MFMR LLC6.3MvenBio Partners LLC4.6MForesite Capital Management IV, LLC4.8MBain Capital Life Sciences Investors, LLC2.7MVIKING GLOBAL INVESTORS LP3.7MEQT Fund Management S.a r.l.3.4MVR Adviser, LLC—DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)3.1MCommodore Capital LP1.9M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| ANRO | Alto Neuroscience, Inc. | 3 | 177.00× |
| TYRA | Tyra Biosciences, Inc. | 6 | 151.71× |
| XFOR | X4 Pharmaceuticals, Inc. | 3 | 132.75× |
| NRIX | Nurix Therapeutics, Inc. | 4 | 128.73× |
| CLDX | Celldex Therapeutics, Inc. | 6 | 124.94× |
| EYPT | EyePoint Pharmaceuticals, Inc. | 4 | 118.00× |
| LYEL | Lyell Immunopharma, Inc. | 3 | 118.00× |
| DMRA | Galecto, Inc. | 3 | 118.00× |
| RLAY | Relay Therapeutics, Inc. | 4 | 101.14× |
| AGIO | Agios Pharmaceuticals, Inc. | 3 | 96.55× |
| ELVN | Enliven Therapeutics, Inc. | 4 | 83.29× |
| MBX | MBX Biosciences, Inc. Common Stock | 3 | 81.69× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (3 analysts)$56.008570.0%
Last Year (8 analysts)$49.506410.0%
Current Price$30.16
Analyst Ratings
11
1
Buy: 11Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$6.14M
20 txns · 8 insiders · 205,965 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | SELL | Bjork Elisabeth | director | 10,000 | $29.32 | $293K | $445K |
| 2026-05-18 | SELL | Modig Berndt | director, officer: Chief Executive Officer | 2,292 | $29.22 | $67K | $4.02M |
| 2026-05-15 | SELL | Abele Stefan Andreas | officer: Chief Technical Ops Officer | 8,748 | $29.82 | $261K | $1.05M |
| 2026-05-15 | SELL | Glassman Robert | director | 10,000 | $29.82 | $298K | $313K |
| 2026-05-15 | SELL | Souverijns Wim | officer: Chief Commercial Officer | 10,000 | $29.92 | $299K | $1.35M |
| 2026-05-01 | SELL | Lu Peng | officer: Chief Medical Officer | 14,166 | $30.17 | $427K | $1.99M |
| 2026-04-30 | SELL | Lesage Anne | officer: Chief Early Development | 37,200 | $30.26 | $1.13M | $1.71M |
| 2026-04-30 | SELL | Lu Peng | officer: Chief Medical Officer | 15,000 | $30.24 | $454K | $2.00M |
| 2026-04-30 | SELL | Schikan Johannes Gerardus Christiaan Petrus | director | 29,070 | $30.32 | $881K | $10.77M |
| 2026-04-29 | SELL | Schikan Johannes Gerardus Christiaan Petrus | director | 3,830 | $30.07 | $115K | $11.55M |
| 2026-04-29 | SELL | Lu Peng | officer: Chief Medical Officer | 3,733 | $30.06 | $112K | $1.87M |
| 2026-04-29 | SELL | Lesage Anne | officer: Chief Early Development | 7,400 | $30.07 | $223K | $1.70M |
| 2026-04-23 | SELL | Lesage Anne | officer: Chief Early Development | 200 | $30.03 | $6K | $1.70M |
| 2026-04-23 | SELL | Lu Peng | officer: Chief Medical Officer | 100 | $30.03 | $3K | $1.98M |
| 2026-04-23 | SELL | Schikan Johannes Gerardus Christiaan Petrus | director | 100 | $30.03 | $3K | $11.65M |
| 2026-04-22 | SELL | Lesage Anne | officer: Chief Early Development | 14,500 | $30.05 | $436K | $1.70M |
| 2026-04-22 | SELL | Lu Peng | officer: Chief Medical Officer | 7,001 | $30.05 | $210K | $1.99M |
| 2026-04-22 | SELL | Schikan Johannes Gerardus Christiaan Petrus | director | 7,000 | $30.05 | $210K | $11.67M |
| 2026-04-16 | SELL | Modig Berndt | director, officer: Chief Executive Officer | 2,292 | $28.60 | $66K | $4.00M |
| 2026-04-09 | SELL | Modig Berndt | director, officer: Chief Executive Officer | 23,333 | $27.74 | $647K | $3.94M |
Order Flow (FINRA, ~3w lag)
9.3%retail+5.4pp
28.7%dark+7.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Pharvaris N.V.: A High-Octane Cash Burn Engine Fueled by Massive Shareholder Dilution
Overall Risk
5/10
Fraud
3/10
Dilution
9/10
Insolvency
2/10
Earnings Overstated
3/10
Hidden Liabilities
4/10
Legal
4/10
Audit Warnings
2/10
Hidden Upside
8/10
Contextually Acceptable
8/10